- Home
- SYRS
as 07-26-2024 4:00pm EST
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Upcoming Earnings Alert:
Get ready for potential market movements as Syros Pharmaceuticals Inc. SYRS prepares to release earnings report on 31 Jul 2024.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 132.8M | IPO Year: | 2016 |
| Target Price: | $14.00 | AVG Volume (30 days): | 76.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.09 - $8.17 | Next Earning Date: | 07-31-2024 |
| Revenue: | $6,981,000 | Revenue Growth: | -43.55% |
| Revenue Growth (this year): | -86.04% | Revenue Growth (next year): | 2259.19% |
Stock Insider Trading Activity of Syros Pharmaceuticals Inc. (SYRS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Richard A | SYRS | Director | Jun 28 '24 | Sell | $5.12 | 34,837 | $178,365.44 | 8,000 | SEC Form 4 |
| Roth David | SYRS | Chief Medical Officer | Apr 3 '24 | Sell | $4.95 | 10,451 | $51,732.45 | 0 | SEC Form 4 |
| Roth David | SYRS | Chief Medical Officer | Mar 31 '24 | Sell | $4.98 | 150 | $747.05 | 10,451 | SEC Form 4 |
| AKKARAJU SRINIVAS | SYRS | Director | Dec 21 '23 | Buy | $4.42 | 904,977 | $3,999,998.34 | 1,786,427 | SEC Form 4 |
| Roth David | SYRS | Chief Medical Officer | Dec 12 '23 | Sell | $4.95 | 6,287 | $31,120.65 | 0 | SEC Form 4 |
| Roth David | SYRS | Chief Medical Officer | Dec 6 '23 | Sell | $3.95 | 6,287 | $24,833.65 | 6,287 | SEC Form 4 |
Latest Syros Pharmaceuticals Inc. News
SYRS Breaking Stock News: Dive into SYRS Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
Zacks
9 days ago
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
Simply Wall St.
a month ago
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week
Business Wire
a month ago
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
GuruFocus.com
2 months ago
Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Thomson Reuters StreetEvents
2 months ago
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
Business Wire
2 months ago
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Business Wire
3 months ago
Syros to Participate in Upcoming Investor Conferences
Compare SYRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SYRS Syros Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.